rituximab every 6 months, and to avoid disruptions of therapy rather than wait longer, given the long dosing interval for rituximab. The panel noted that rituximab is used in SLE without an indication approved by the US Food and Drug Administration (FDA) but also noted that it has been included in SLE treatment guidelines This recommendation has changed since the prior guideline in part because of the additional indication for the use of belimumab in severe SLE including nephritis, as well as